Prognostic effect of primary tumor location in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC)

被引：0
|
作者：
Macarulla Mercade, T. [1 ,2 ]
Wang-Gillam, A. [3 ]
Chen, L. [4 ]
Blanc, J. [5 ]
Lee, K. [6 ]
Bodoky, G. [7 ]
Dean, A. [8 ]
Siveke, J. [9 ,10 ,11 ]
Mirakhur, B. [12 ]
Chen, J. [13 ]
de Jong, F. [14 ]
机构：
[1] Vall dHebron Univ Hosp HUVH, Barcelona, Spain
[2] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[3] Washington Univ, Div Oncol, St Louis, MO USA
[4] Natl Hlth Res Inst, Natl Inst Canc Res, Miaoli, Taiwan
[5] Hop Haut Leveque, Bordeaux, France
[6] Seoul Natl Univ Hosp, Seoul, South Korea
[7] Szent Laszlo Hosp, Dept Oncol, Budapest, Hungary
[8] St John God Hosp Subiaco, Subiaco, WA, Australia
[9] Univ Hosp Essen, West German Canc Ctr, Essen, Germany
[10] German Canc Consortium DKTK, Essen, Germany
[11] German Canc Res Ctr, Essen, Germany
[12] Ipsen Biopharmaceut Inc, Basking Ridge, NJ USA
[13] Shire Plc, Cambridge, MA USA
[14] Shire Int GmbH, Glattpk Opfikon, Switzerland
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P - 150
引用
收藏
页数：2
相关论文
共 50 条
  • [41] CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) 6 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
    Chen, L-T.
    Wang-Gillam, A.
    Shan, Y-S.
    Mercade, T. Macarulla
    Blanc, J. F.
    Hubner, R.
    Chiu, C-F.
    Schwartsmann, G.
    Siveke, J.
    Belanger, B.
    de Jong, F.
    Mamlouk, K.
    von Hoff, D.
    ANNALS OF ONCOLOGY, 2017, 28
  • [42] Safety and clinical activity of oleclumab (O) ± durvalumab (D) plus chemotherapy (CT) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A phase 1b/2 randomized study
    Coveler, Andrew L.
    Reilley, Matthew
    Zalupski, Mark
    Macarulla, Teresa
    Fountzilas, Christos
    Castanon Alvarez, Eduardo
    Nagrial, Adnan
    Volodymyrivna Uboha, Nataliya
    Frentzas, Sophia
    Overman, Michael J.
    Noonan, Anne M.
    Messersmith, Wells A.
    Pavlakis, Nick
    Mettu, Niharika B.
    Smith, Paul
    Murtomaki, Elina
    Bragulat, Veronique
    Cooper, Zachary A.
    Kumar, Rakesh
    Spigel, David
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [43] NAPOLI-3: A randomized, open-label Phase 3 study of liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin (NALIRIFOX) versus nab-paclitaxel plus gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)
    Goetze, T.
    Melisi, D.
    Macarulla, T.
    Pazo Cid, A. R.
    Chandana, R. S.
    De La Fouchardiere, C.
    Dean, A.
    Kiss, I.
    Lee, Jin W.
    Van Cutsem, E.
    Paulson, S.
    Bekaii-Saab, T.
    Pant, S.
    Hubner, R.
    Xiao, Z.
    Chen, H.
    Benzaghou, F.
    O'Reilly, E.
    Wainberg, A. Z.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 12 - 14
  • [44] A phase 2, open-label, multicenter study of durvalumab (MEDI4736) tremelimumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): ALPS.
    O'Reilly, Eileen Mary
    Oh, Do-Youn
    Lee, Myung Ah
    Dhani, Neesha
    Armstrong, Jon
    Belli, Riccardo
    Ferro, Salvatore
    Ben, Yong
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [45] Association of BRCA1/2 pathogenic variants with primary tumor location and metastatic organotropism in pancreatic adenocarcinoma.
    Hood, Ryan
    Rathore, Srishti
    Seewald, Nicholas J.
    Reiss, Kim Anna
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Overall survival (OS) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with first-line (1L) FOLFIRINOX (FFX): Bridging the gap between the NAPOLI 3 trial and real-world practice.
    Cockrum, Paul
    Chang, Rose
    Yu, Louise Huafeng
    Xu, Chunyi
    Duh, Mei Sheng
    Kim, George P.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
  • [47] CD40 agonist mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Interim efficacy results of the OPTIMIZE-1 phase 1b/2 study
    Van Laethem, Jean-Luc
    Geboes, Karen P.
    Cassier, Philippe A.
    Borbath, Ivan
    Lambert, Aurelien
    Mitry, Emmanuel
    Prenen, Hans
    Blanc, Jean-Frederic
    Pilla, Lorenzo
    Garrote, Mercedes Rodriguez
    Cid, Roberto A. Pazo
    Gallego, Inmaculada
    Feliu, Jaime
    Nordbladh, Karin
    Ellmark, Peter
    Carlsson, Malin
    de Coana, Yago Pico
    Ambarkhane, Sumeet V.
    Macarulla, Teresa
    CANCER RESEARCH, 2024, 84 (02)
  • [48] Prognostic value of disseminated tumor cells in unresectable pancreatic ductal adenocarcinoma: a prospective observational study
    Nordgard, Oddmund
    Lapin, Morten
    Tjensvoll, Kjersti
    Oltedal, Satu
    Edland, Karin Hestnes
    Neverdahl, Nicolay Bore
    Fostenes, Dmitrij
    Garresori, Herish
    Glenjen, Nils
    Smaaland, Rune
    Gilje, Bjornar
    BMC CANCER, 2022, 22 (01)
  • [49] Prognostic value of disseminated tumor cells in unresectable pancreatic ductal adenocarcinoma: a prospective observational study
    Oddmund Nordgård
    Morten Lapin
    Kjersti Tjensvoll
    Satu Oltedal
    Karin Hestnes Edland
    Nicolay Bore Neverdahl
    Dmitrij Fostenes
    Herish Garresori
    Nils Glenjen
    Rune Smaaland
    Bjørnar Gilje
    BMC Cancer, 22
  • [50] Efficacy and safety of liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who previously received gemcitabine (gem)-based therapy: Post-hoc analysis of the NAPOLI-1 trial
    Chen, Li-Tzong
    Wang-Gillam, Andrea
    Yanshen, Shan
    Macarulla, Teresa
    Blanc, Jean-Frederic
    Hubner, Richard
    Chiu, Chang-Fang
    Schwartsmann, Gilberto
    Siveke, Jens T.
    Pipas, J. Marc
    Belanger, Bruce
    de Jong, Floris
    Mamlouk, Khalid
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
12345